Previous 10 | Next 10 |
JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses PR Newswire Sale reduces liabilities by $17.6 million and entails at least $24 Million in future payments LAS VEGAS , March 22, 2023 /PRNewswire/ -- JanOne (Nasd...
2023-03-17 08:33:13 ET Diebold Nixdorf DBD -28% on liquidity concerns . Sarepta Therapeutics SRPT -18% on FDA advisory meeting for its muscular dystrophy treatment . ThermoGenesis ( THMO ) -19% . First Republic Bank FRC -15% after suspending d...
2023-03-16 08:13:55 ET ThermoGenesis Holdings ( NASDAQ: THMO ) +56% . PureCycle Technologies ( PCT ) +17% Q4 earnings call release JanOne ( JAN ) +30% . UiPath ( PATH ) +15% Q4 Earnings call release Biora Therapeutics ( ...
JanOne to Present Important Trial Results at Annual Meeting of American Society of Interventional Pain Physicians PR Newswire JAN 123's in vitro study on low dose naltrexone vies for the Society's "Best Research Abstract of the Year" LAS VEGAS , Feb. 22, ...
JanOne Charts Ambitious Strategic Course for Non-Addictive Pain Management PR Newswire In meetings hosted by Nasdaq MarketSite , the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addicti...
JanOne Inc. Completes Acquisition of Soin Therapeutics, LLC PR Newswire The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS , Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a company ...
JanOne ( NASDAQ: JAN ) has executed a term sheet to acquire Soin Therapeutics and its product, a patent-pending, novel formulation of low dose naltrexone. The product, that JanOne will name Jan123, is being developed for the treatment of Complex Regional Pain Syndrome, a s...
JanOne Inc. Executes Term Sheet to Acquire Soin Therapeutics LLC PR Newswire The acquisition of Soin will provide JanOne with its second clinical stage product LAS VEGAS , Sept. 16, 2022 /PRNewswire/ -- JanOne Inc. ("JanOne") (Nasdaq: JAN), a ...
JanOne Announces Closing of $6.0 Million Common Stock Offering Net proceeds will help support planning of clinical trials for JAN101, the company's lead drug candidate PR Newswire LAS VEGAS , Feb. 2, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a ...
Artelo Biosciences (ARTL) +78%.Moleculin Biotech (MBRX) +49% on announcing 100% survival achieved in Osteosarcoma Lung Metastases Animal Model.DURECT (DRRX) +42% after FDA approval for Posimir.Holicity (HOLUU) +38% on plan to take rocket maker Astra public.Tiziana Life Sciences...
News, Short Squeeze, Breakout and More Instantly...
JanOne Inc. Company Name:
JAN Stock Symbol:
NYSE Market:
Shares of JanOne Inc. (NASDAQ: JAN) traded at a new 52-week high today and are currently trading at $3.29. So far today, approximately 102.47k shares have been exchanged, as compared to an average 30-day volume of 135.62k shares. JanOne Inc., a clinical-stage biopharmaceutical company, focuse...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...